Background: BACE1 is the rate-limiting enzyme in the cleavage of amyloid precursor protein to A␤ peptides. Results: Retinoic acid blocks the BACE1 gene up-regulation during inflammation via the inhibition of NFB. Conclusion: Retinoic acid suppresses aspects of neuroinflammation in rodent models of Alzheimer disease including elevated BACE1 transcription. Significance: Retinoids may have an important role in limiting progression of Alzheimer disease.
Insulin resistance and neuroinflammation have emerged as two likely key contributors in the pathogenesis of Alzheimer disease (AD), especially in those sporadic AD cases compromised by diabetes or cardiovascular disease. Amyloid-␤ (A␤) deposition and its associated inflammatory response are hallmarks in sporadic AD brains. Elevated expression and activity of ␤-secretase 1 (BACE1), the rate-limiting enzyme responsible for the ␤-cleavage of amyloid precursor proteins to A␤ peptides, are also observed in sporadic AD brains. Previous studies have suggested that there is therapeutic potential for retinoic acid in treating neurodegeneration based on decreased A␤. Here we discovered that BACE1 expression is elevated in the brains of both Tg2576 transgenic mice and mice on high fat diets. These conditions are associated with a neuroinflammatory response. We found that administration of all-trans-retinoic acid (atRA) down-regulated the expression of BACE1 in the brains of Tg2576 mice and in mice fed a high fat diet. Moreover, in LPStreated mice and cultured neurons, BACE1 expression was repressed by the addition of atRA, correlating with the antiinflammatory efficacy of atRA. Mutations of the NFB binding site in BACE1 promoter abolished the suppressive effect of atRA. Furthermore, atRA disrupted LPS-induced nuclear translocation of NFB and its binding to BACE1 promoter as well as promoting the recruitment of the corepressor NCoR. Our findings indicate that atRA represses BACE1 gene expression under inflammatory conditions via the modulation of NFB signaling.
Compelling evidence suggests that in Alzheimer disease (AD), 4 amyloid-␤ (A␤) deposition is associated with marked inflammatory response via activated microglias and the recruitment of astrocytes (1) . A␤ peptides are derived from amyloid precursor protein (APP) by sequential proteolytic cleavage via ␤-secretase (BACE1) and ␥-secretase (2) . In AD brains, the specific regions affected by A␤ deposition are correlated with elevated levels of BACE1 expression and activity. Together with the observation of diminished amyloid pathology in BACE1deficient mice (3), these findings define a central role of BACE1 in APP processing and A␤ generation/deposition, which makes it one of the most important therapeutic targets of AD.
BACE1 expression is tightly regulated at multiple levels from transcription to translation (3, 4) . At the transcriptional level, BACE1 expression is positively or negatively regulated by a number of transcription factors under basal and cell-stressed conditions (5) . We recently reported that that BACE1 transcription is up-regulated by metabolic risk factors and that the key metabolic regulatory pathway of AMPK-SIRT1-PGC-1␣ (where AMPK is AMP-activated protein kinase) suppressed BACE1 transcription by directly acting on the first PPAR-responsive element (PPRE) in the BACE1 gene both in cultured neurons and in vivo settings (calorie restriction, etc.) (6, 7) . Although the identification of several putative binding sites for NFB and PPAR␥ in BACE1 promoter strongly implicates its regulation under inflammatory condition, compelling evidence is lacking.
Retinoic acid (RA) is a metabolic product of vitamin A and is involved in several essential biological processes including proliferation, differentiation, survival, and apoptosis (8 -12) . In general, RA modulates its effects by binding to nuclear retinoic acid receptors (RARs) and retinoid X receptors (RXRs). RARs are ligand-dependent transcription factors that bind response elements as heterodimers with RXRs to regulate a large number of target genes (over 500 so far). RA exists in three main stereoisomeric forms, all-trans-retinoic acid (atRA), 13-cis RA, and 9-cis RA, among which atRA is the primary biologically active form in brain. RA also exerts anti-inflammatory efficacy via repressing the expression of inflammatory factors such as IL-6, IL-12, and TNF␣ (13) (14) (15) (16) and modulating NFB signaling (17, 18) .
The RAR/RXR nuclear receptors are being pursued as major drug targets for various diseases such as cancer and metabolic syndrome. The importance of retinoid signaling in AD has recently emerged. Clinical and experimental studies strongly suggest that disruption of RA signaling correlates with AD pathogenesis (19) . When compared with normal aged controls, AD patients have lower serum concentrations of vitamin A and ␤-carotene (20, 21) . Defective RA transport and function are also observed in AD brains (22, 23) . In vitamin A-deprived rodents, RAR expression is down-regulated, and most strikingly, this is accompanied by AD-like hallmarks including accumulation of A␤ peptides, loss of hippocampal long-term potentiation, and memory deficits (24 -28) . These effects were largely reversed by the administration of RA (29, 30) . Taken together, these data provide strong rationale investigating RA-based therapy in AD (31) (32) (33) (34) .
Although atRA has been reported to attenuate A␤ deposition in APP/PS1 double-transgenic mice (30), the mechanism remains unclear. It has been reported that RA can reduce A␤ production via activating non-amyloidogenic ␣-secretase (35, 36) . Here we aim to investigate the potential modulation of BACE1 expression by RA and its underlying mechanism. Based on the known potent modulatory role of RA in immune response (13) (14) (15) (16) , we speculated that RA might be able to suppress BACE1 expression under inflammatory conditions. It should be stressed that in comparison with the peripheral system, the anti-inflammatory role of RA in CNS remains largely elusive. To test our hypothesis, we examined the expression of BACE1 in atRA-treated Tg2576, high fat diet, and LPS-challenged mice. These conditions have all been reported to induce inflammatory events in the brain (34, 37, 38) . We further investigated the underlying molecular mechanism using in vitro cultured rat primary neurons.
Experimental Procedures
Animals-All animal care protocols and procedures were performed in accordance with the Animal Scientific Procedures Act and with approval of the University of Tennessee Animal Care and Use Committee. High fat diet (HFD) was given to C57BL/6 mice as described (39) . atRA (R2625, Sigma) dissolved in 5% DMSO/corn oil and LPS from Escherichia coli 055:B5 (L2880, Sigma) in PBS were given to C57BL/6 mice by intraperitoneal injection at 20 and 5 mg/kg, respectively. For Tg2576 transgenic mice (6 -8 months) and HFD mice (8 -9 months), atRA was given every 2 days for 12 and 8 weeks, respectively. For the acute inflammatory model, C57BL/6 mice were administrated atRA every other day for 3 days and then treated with LPS for 6 h or overnight.
Cell Culture and Drug Treatment-Rat primary cortical neurons were prepared as described (40) and maintained at 37°C in a humidified incubator with 9.5% CO 2 . HEK 293 and Neuro-2a (N2a) cells were cultured in DMEM (Cellgro) with 10% FBS (HyClone) and 50% DMEM/50% Opti-MEM I (Gibco) with 5% FBS, respectively, and maintained at 37°C in a humidified incubator with 5% CO 2 . atRA stocks in DMSO and LPS stocks in PBS were stored at Ϫ80°C. For each experiment, atRA or LPS was diluted from its stock solution and added to the growth medium at the indicated concentrations; 0.1% (v/v) solvent was used as vehicle control.
Western Blot Analysis-Cell and cortical tissue lysates were prepared in radioimmunoprecipitation assay lysis buffer. N2a nuclear extracts and cytoplasmic extracts were prepared using the nuclear extract kit (Active Motif). The same amount of total proteins was resolved on Novex 4 -20% Tris-glycine gel (Life Technologies), and the subsequent Western blot was performed as described (Wang et al. (7) ) using the following antibodies: rabbit anti-BACE1 (1:250; AB5940, Millipore), mouse anti-␤-actin (1:5000; A2228, Sigma), mouse anti-tubulin (1:5000; T6074, Sigma), rabbit anti-phospho-IB (1:205; 2859P, Cell Signaling), mouse anti-IB (1:250; 4814P, Cell Signaling), mouse anti-NFB p65 (1:1000; sc-71676, Santa Cruz Biotechnology), and rabbit anti-phospho-NFB p65 (1:250; 3031S, Cell Signaling).
Immunohistochemistry and Immunocytochemistry-After perfusion with 4% paraformaldehyde/PBS, mouse brains were cryopreserved in 30% (w/v) sucrose/PBS at 4°C overnight. Brain samples embedded in OCT were cut into coronal 20-m sections and mounted on a glass. Brain sections were blocked at room temperature for 1 h in normal goat serum buffer (10% normal goat serum, 0.2% Triton X-100, and 0.02% NaN 3 in TBS) and incubated with primary antibodies at 4°C overnight. The subsequent incubation of fluorescence-conjugated secondary antibodies was performed at room temperature for 2 h. To visualize nucleus, sections were counterstained with DAPI (Invitrogen). After incubation with antibodies, all sections were washed three times with PBS, 10 min each time. The fluorescence was examined with microscopy.
For immunocytochemistry, drug-treated rat primary neurons were briefly rinsed with PBS and fixed with 4% paraformaldehyde, 0.12 M sucrose in PBS. Neurons were permeabilized in 0.3% Triton X-100 for 5 min. Fixed neurons were blocked in 10% BSA in PBS for 1 h at room temperature and incubated in primary antibodies at 4°C overnight. Neurons were then incubated in fluorescence-conjugated secondary antibodies at room temperature for 1 h and counterstained with DAPI to visualize nucleus. The antibodies used were rabbit anti-BACE1 (1:50; AB5940, Millipore), mouse anti-NeuN (1:30; MAB377, Chemicon), mouse anti-NFB p65 (1:100; sc-71676, Santa Cruz Biotechnology), and Alexa Fluor 488 and 594 secondary antibody (1:500; Invitrogen).
Quantitative Real-time RT-PCR-RNA was prepared using TRIzol (Invitrogen) according to the manufacturer's instructions. Single-stranded cDNA was synthesized from 1 g of total RNA using High Capacity cDNA reverse transcription kits (Applied Biosystems). Quantitative real-time PCR was performed with RealMasterMix SYBR ROX (5 Prime) according to the manufacturer's protocols using the same rat and mouse GAPDH primers, as well as rat BACE1 primers. Primers for TNF␣ (forward 5Ј-CCCTCACACTCAGATCATCTTCT-3Ј and reverse 5Ј-GCTACGACGTGGGCTACAG-3Ј), IL-6 (forward 5Ј-GCTACCAAACTGGATATAATCAGGA-3Ј and reverse 5Ј-CCAGGTAGCTATGGTACTCCAGAA-3Ј), and Toll-like receptor-4 (TLR4) (rat forward 5Ј-GGATGATGCC-TCTCTTGCAT-3Ј and reverse primer 5Ј-TGATCCATGC-ATTGGTAGGTAA-3Ј; mouse forward 5Ј-GGACTCTGATC-ATGGCACTG-3Ј and reverse 5Ј-CTGATCCATGCATTGG-TAGGT-3Ј) were used in the present studies.
Transient Transfection and Luciferase Assay-HEK 293 cells were seeded at 4 -5 ϫ 10 4 cells/well in a 24-well plate the day before transfection. Transient transfection was conducted using Lipofectamine 2000 (Invitrogen) following the procedure provided by the manufacturer. Deletion constructs and mutants of rat BACE1 promoter were described (Wang et al. (7) ); the expression vectors of RXR␣, RAR␣, RAR␤, and RAR␥ were kind gifts from Dr. Xiao-kun Zhang (Sanford-Burnham Medical Research Institute) and Dr. Philippe Lefebvre (INSERM, UMR1011, F-59000, Lille, France). Drug treatment was performed 5 h after transfection. Luciferase assays were conducted with the Dual-Luciferase reporter assay system (E1910, Promega) in a TD-20/20 luminometer.
ChIP Assay-ChIP assays were performed using the Chromatin Immunoprecipitation kit (17-295, Upstate EMD Millipore) according to the manufacturer's instructions. Chromatin fragments from mouse cortex were prepared as described (7) . 30 mg of tissues were used for each ChIP/antibody with mouse anti-NFB p65 (sc-71676, Santa Cruz Biotechnology), goat anti-NCoR (sc-1609, Santa Cruz Biotechnology), mouse anti-PPAR␥ (81B8) (2443, Cell Signaling), and rabbit anti-RXR␣ (sc-553, Santa Cruz Biotechnology). The following primers were used in PCR assays: for mouse BACE1 promoter NFB site, forward 5Ј-GAGAGCCCCTCAGCTTCTTT-3Ј and reverse 5Ј-GGGGCCCTGATAGCTTAAAA-3Ј; for rat BACE1 NFB site, forward 5Ј-ATGGTGGCTGGATTTTATCGAGG-3Ј and reverse 5Ј-GTGAATTTGTCTGTGCCTTTG-3Ј; for rat BACE1 PPRE site, 5Ј-GAGTAATGTTGGTATGCCTC-3Ј and reverse 5Ј-GGGATGAGAGTATGTCAGTC-3Ј.
Statistical Analysis-All quantitative data are presented as means Ϯ S.D. Comparisons between groups were analyzed by Student's t test.
Results

atRA Treatment Reduces Cortical BACE1 Expression in Tg2576 and HFD Mice-We tested the effect of systemic administration of atRA on BACE1 expression in symptomatic
Tg2576 mice overexpressing the transgene of human Swedish mutant of APP 695 . These mice expressed much higher BACE1 levels as compared with non-transgenic mice at the same age ( Fig. 1, A and B) . Continuous atRA treatment for 12 weeks significantly reduced BACE1 protein levels by 30% in the cortex of Tg2576 mice as compared with the vehicle-treated group (Fig.  1, A and B) . Notably, BACE1 expression was only slightly decreased in atRA-treated non-transgenic mice, although there was no statistical significance due to the individual variation.
These data suggest that atRA is more effective in inhibiting BACE1 under inflammatory conditions.
In a previous study (39) , neuroinflammation and a cognitive deficit in young WT C57BL/6 (B6) mice were induced by a high fat, high cholesterol diet (21% fat from milk with enriched cholesterol at 1.25%, HFD). We also found that young C57BL/6 mice consuming this HFD for 8 weeks demonstrated increased BACE1 expression (7) , neuroinflammation, and learning/memory deficits (data not shown). Therefore, we tested the effect of atRA on the elevated BACE1 expression in HFD mice. As shown in Fig. 1 , C and D, atRA administration for 8 weeks dramatically reduced BACE1 expression levels in the cortex of HFD mice to basal level in the control mice on the chow diet. Furthermore, quantitative RT-PCR analysis revealed a significant decrease in the expression of the proinflammatory factors TNF␣ and IL-6 in atRA-treated HFD mice (Fig. 1, E and F) , suggesting that the suppressive effect of atRA on BACE1 expression in Tg2576 and HFD mouse brains is correlated with its anti-inflammatory role.
atRA Represses LPS-induced BACE1 Expression in Vitro and in Vivo-Although the Tg2576 and HFD mice develop a chronic inflammatory condition in the CNS, systemic LPS administration induces acute brain inflammation, which also leads to impaired memory (41) . We injected LPS intraperitoneally into C57BL/6 mice and observed dramatically increased TNF␣ and IL-6 expression in the cortex of LPS-treated mice several hours later (Fig. 2, A and B) . The increased expression of TNF␣ and IL-6 was significantly inhibited by atRA pretreatment (Fig. 2, A and B ), suggesting that atRA blocks LPS-induced acute neuroinflammation. Therefore, we tested the effect of atRA on BACE1 expression using this model. In a Western blot analysis with cortical lysates, a complete correction of BACE1 expression was observed in the atRA-LPStreated mice as compared with the LPS-treated mice (Fig. 2 , C and D). Because astrocytes and microglias are the major sources of neuroinflammation in vivo, we sought to investigate whether LPS-induced BACE1 regulation is primarily a neuronal or glial event. Immunohistochemical analysis ( Fig. 2E ) revealed that the LPS-induced BACE1 co-localized with NeuN (a neuronspecific nuclear protein) and that this BACE1 was inhibited by atRA treatment. Neurons may directly respond to inflammatory agents due to neuronal expression of cytokine receptors such as the LPS and TNF␣ receptors (42, 43) .
atRA Represses BACE1 Expression at the Transcriptional Level-Given the suppressive effects of atRA in vivo, we speculated that atRA would modulate BACE1 gene transcription in vitro. Indeed, in cultured neurons, atRA (0.01-1 M) not only reduced BACE1 protein levels in a dose-dependent manner (Fig. 3, A and B) , but also decreased BACE1 mRNA expression in neurons ( Fig. 3C ). Moreover, when HEK 293 cells were transfected with a vector containing the BACE1 promoter driving the luciferase reporter gene, atRA treatment caused an ϳ50% reduction in BACE1 promoter activity ( Fig. 3D ). Together, these data suggest that atRA represses basal BACE1 expression at the transcriptional level.
There are four potential RAR-PPAR-RXR-responsive elements predicted in BACE1 promoter (7, 40) . To determine whether the repressive effect of atRA on BACE1 promoter depends on retinoid receptors, we first tested the impact of overexpressed receptors on the co-expressed BACE1-luciferase construct. In cotransfection experiments with the expression vectors for human RXR␣, RAR␣, RAR␤, and RAR␥ isoforms and the rat BACE1 promoter-luciferase reporter in HEK 293 cells, we found that none of these receptors significantly affected basal BACE1 promoter activity except for RAR␥ (ϳ30% reduction) (Fig. 3E ). In addition, overexpression of these receptors did not increase the repressive action of atRA on BACE1 promoter activity. Moreover, atRA treatment significantly induced expression of all RAR isoforms in cultured neurons ( Fig. 3F) . Interestingly, the combination of PGC-1␣ overexpression with atRA treatment did not cause further BACE1 suppression, nor did the overexpression of PPAR␥ (data not shown), suggesting that the expression levels of these receptors/cofactors are not a limiting factor for the effect of atRA. To further investigate the potential involvement of these factors, we then tested several agonists/antagonists including SR1664 and GW9662, a PPAR␥ agonist and antagonist, respectively; bexarotene, an RXR agonist; and AGN 194310, an RAR panantagonist. Consistent with the overexpression data, none of these compounds exerted significant effect on atRA-repressed BACE1 repression (data not shown). Thus, the abundance of retinoid receptors does not appear to directly contribute to the suppressive effect of atRA on BACE1 transcription. We used 1 M atRA in all of our subsequent in vitro studies because it is equivalent to the in vivo RA concentration in the brain (ϳ2-5 ng/g) as measured by LC-MS (44, 45) .
Because BACE1 was reported to be up-regulated in PPAR␥ Ϫ/Ϫ mouse embryonic fibroblast cells and PPAR␥ agonists were able to suppress BACE1 transcription under inflammatory conditions (46), we tested the effect of atRA in neurons challenged with TNF␣ (10, 30 ng/ml) and LPS (1 g/ml) for 4 h. We found that atRA completely reduced BACE1 expression induced by these cytokines to levels even lower than the untreated control ( Fig. 4A ), which correlated with its effect on BACE1 mRNA (Fig. 4B ). Because TNF␣ induction/release is usually a result of activated NFB in microglial cells, we predicted that atRA would suppress the NFB activation, which may partially mediate its repressive effect on BACE1 gene transcription.
NFB Mediates the Suppressive Effect of atRA on BACE1 Transcription-Both the NFB and the PPRE site are adjacently located in the 5Ј end of the BACE1 promoter. To identify the atRA targeting region in BACE1 promoter, we generated a series of BACE1 deletion mutants ( Fig. 5A ) and compared their promoter activity in the presence of atRA (Fig. 5B) . The atRA did not suppress F2-F7 promoters, suggesting that the Ϫ1541 atRA Modulates NFB Signaling to Repress BACE1 Transcription SEPTEMBER 11, 2015 • VOLUME 290 • NUMBER 37
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to Ϫ1327 region contains elements that mediate the suppressive effect of atRA. Of note, regulatory elements for NFB and PPAR have been found in this region that repress BACE1 expression under basal and inflammatory conditions, respectively (47) . Indeed, disruption of NFB element via mutagenesis not only led to increased BACE1 transcription but also abolished the suppressive effect of atRA under basal conditions (Fig.  5C ). These data suggest that NFB plays a critical role in atRA-mediated BACE1 repression. On the other hand, atRA still repressed the promoter activity of BACE1 PPRE mutant, although the effect was reduced by 20% ( Fig. 5C ), suggesting a minor contribution through the PPRE to atRA-mediated BACE1 repression. In addition, we tested whether atRA would inhibit the LPS induction of the BACE1 promoter. As shown in Fig. 5D , atRA blocked the LPS induction of the wild type but not the NFB mutant promoter. In N2a cells, atRA eliminated the atRA Modulates NFB Signaling to Repress BACE1 Transcription LPS stimulation of BACE1 mRNA. Furthermore, an IB kinase (IKK) inhibitor, EF-24, abolished the suppressive effect of atRA on BACE1 mRNA (Fig. 5E) ; surprisingly, the inhibitor by itself also inhibited BACE1 mRNA.
atRA Inhibits Inflammatory NFB Activation-We further tested whether atRA modulates NFB activity. The IB kinase enzyme complex is a crucial part of the upstream NFB signal transduction cascade. The IB␣ protein inactivates the NFB transcription factor by masking the nuclear localization signals of NFB proteins and keeping them sequestered in an inactive state in the cytoplasm. IB kinase specifically phosphorylates the inhibitory IB␣ protein, resulting in the dissociation of IB␣ from NFB, in turn freeing NFB to migrate into the nucleus and activate the expression of target genes. In a Western blot analysis with cortical lysates (Fig. 6,   A and B) , LPS-induced phosphorylation of IB␣ was abolished by atRA treatment, which was accompanied by the inhibition of the phosphorylation of NFB p65 subunit, indicating that atRA inhibits LPS-induced NFB activation. Moreover, the nuclear localization of NFB p65 subunit induced by LPS was also inhibited by atRA treatment in N2a cell fraction analysis (Fig. 6C ) and immunofluorescence staining assay (Fig. 6D) .
atRA Disrupts NFB Binding to the BACE1 Promoter-To test whether atRA influences the binding of NFB to BACE1 promoter, we performed in vitro and in vivo ChIP assays. As shown in Fig. 7A , in a ChIP assay with rat primary neurons (Fig.  7A) , atRA inhibited LPS-induced NFB p65 binding to BACE1 promoter. Meanwhile, the corepressor NCoR was recruited to the NFB site in BACE1 promoter. Consistent with the data FIGURE 5. NFB mediates the suppressive effect of atRA on BACE1 expression. A, schematic diagram of rat BACE1 promoter (1.54 kb) in pGL3-Basic. F7, F8, F9, and F2 represent four BACE1 promoter deletions. luc, luciferase. B, atRA effect on BACE1 promoter and its deletions. Rat BACE1 promoter and its deletions were transfected into HEK 293 cells, and then cells were exposed to 1 M atRA overnight. C, atRA effect on the activity of BACE1 promoter mutants based on luciferase activity. HEK 293 cells were transfected with rat BACE1 promoter vector and its mutants (NFBmut and PPREmut) and treated overnight with 1 M atRA. D, atRA effect on the activity of BACE1 promoter and its mutant NFBmut with or without LPS stimulation. HEK 293 cells were transfected with rat BACE1 promoter vector or NFB mutant and then treated overnight with 1 g/ml LPA in the presence of or in the absence of atRA. n.s. indicates non-statistically significant by Student's t test. E, atRA effect on BACE1 mRNA expression with LPS or EF-24 treatment. N2a cells were treated with 1 g/ml LPS for 6 h or 5 M EF-24 for 30 min in the presence of or in the absence of atRA. BACE1 mRNA level was determined by RT-qPCR. Data represent expression levels relative to GAPDH ϫ 1000; means Ϯ S.D. n ϭ 3, *, p Ͻ 0.05 and **, p Ͻ 0.01 by Student's t test. For luciferase assay, luciferase values were normalized to Renilla luciferase values expressed by co-transfected pRL-SV40 vector. Mean values of vehicle-treated cells were set to 1, means Ϯ S.D. n Ն 3, *, p Ͻ 0.05 and **, p Ͻ 0.01 by Student's t test.
atRA Modulates NFB Signaling to Repress BACE1 Transcription SEPTEMBER 11, 2015 • VOLUME 290 • NUMBER 37 JOURNAL OF BIOLOGICAL CHEMISTRY 22537 described earlier, binding of RXR␣, PPAR␥, and PGC-1␣ to the PPRE-RXR site was not significantly affected by atRA treatment (Fig. 7B) . Most importantly, similar effects of atRA were detected in vivo by ChIP analysis with mouse cortex (Fig. 7C) , confirming recruitment of NCoR to the NFB site.
Discussion
Nuclear receptors and their ligands are important regulators of gene expression. In our previous work (7) , we showed that PPAR␥ and the coactivator PGC-1␣ inhibited the expression of BACE1. In this study, we explored the regulation of the BACE1 FIGURE 6. atRA inhibits inflammatory NFB activation. A, C57BL/6 mice were treated with LPS for 6 h with or without atRA administration as described under "Experimental Procedures." Hippocampal proteins, BACE1, NFB p65, phosphorylated NFB p65 (p-NFB p65), IB-␣, and phosphorylated IB-␣ (p-IB-␣) were detected by Western blot, with ␤-actin as loading control. B, quantification of Western blots from panel A based on three independent experiments *, p Ͻ 0.05 and **, p Ͻ 0.01 by Student's t test. C and D, atRA effect on the nuclear translocation of NFB p65. N2a cells were exposed to 1 g/ml LPS for 1 h in the presence of or in the absence of 10 M atRA. C, NFB in both nuclear and cytoplasmic extracts was detected by Western blot. Cytoplasmic ␣-tubulin was used as loading control. D, NFB p65 unit was stained in green, and nuclei were visualized by DAPI counterstain. Scale bar ϭ 20 m. atRA Modulates NFB Signaling to Repress BACE1 Transcription gene by atRA. Although a large number of genes are induced by atRA (48 -50) , we found that atRA can suppress BACE1 gene transcription. In addition, we discovered that the mechanism by which atRA suppressed BACE1 gene expression involved the inhibition of NFB activity. To our knowledge, this is the first report of retinoids blunting the expression of the BACE1 gene. BACE1 is the most important rate-limiting enzyme in AD development, and its expression is modulated by the interplay of the retinoid and NFB pathways.
RA Negatively Regulates the BACE1 Gene-Although more than 500 target genes have been found to be up-regulated by RA, only ϳ3-5 genes were reported to be down-regulated, and only one of these negatively regulated genes was studied at a molecular level (51) . The effect of RA on AP-1-responsive genes was reported to involve inhibition of AP-1 binding to the response element (52) . A second group also found that RA disrupted the recruitment of AP-1 and coactivators to AP1-regulated promoters (53) . In both studies, the direct binding of RAR to the AP-1 site was not required. Other studies have suggested that RA activated PKC to down-regulate the MMP (matrix metalloproteinase) gene (54) . Our data indicate that the abundance of the RARs is not limiting with respect to inhibiting BACE1 expression, and we were not able to identify a specific RAR isoform that mediates this effect. Overexpression of RAR␥ appeared to modestly enhance the suppressive effect of atRA on BACE1 promoter activity (Fig. 3E ). However, this isoform was reported to be nearly undetectable in the brain (55) and raises the question of how relevant this specific isoform is to BACE1 regulation. On the other hand, a more recent study indicates a crucial role of this isoform in activity-dependent protein synthesis at synapses pertinent to synaptic plasticity (56) .
RA-mediated Regulation of NFB Signaling-Elegant work from Bromhoff's group (17) using a transgenic murine NFBluciferase reporter model demonstrated an over 2-fold increase in NFB activity in immune organs (lymph node and thymus) in vitamin A-deficient mice. This elevation of NFB activity could be reversed by a single administration of atRA. Interestingly, in the same model system, a single injection of the RAR pan-antagonist, AGN 194310, also resulted in a marked, transient induction of whole-body luminescence. It remains to be clarified which RARs are involved in mediating RA's inhibition of LPS-induced NFB activity in our models of neuroinflamma-tion. Further studies from the Bromhoff laboratory (57) showed that atRA repressed LPS-induced whole-body luminescence.
Regarding the mechanism by which atRA modulates NFB activity, our compelling evidence based on in vitro and in vivo biochemical and immunocytochemical approaches demonstrated that atRA activates and stabilizes IB␣ via reducing its phosphorylation status. In addition, atRA blocks the specific p65 subunit of NFB and its nuclear translocation. Although we did not directly measure NFB-IB␣ complexes, our data suggest an enhanced IB␣ protein stability and association with the p65/50 upon atRA treatment. We did not detect significant effect of atRA on the gene expression of p65 (data not shown). Furthermore, atRA modulates the expression of proinflammatory factors and their receptors. The expression of TNF␣ and IL-6 was significantly decreased in atRA-treated HFD mice and LPS-treated mice (Figs. 1, E and F, and 2, A and B) . Besides inducing the expression of proinflammatory factors, systemic LPS administration elevates pulmonary TLR4 expression (58) . By quantitative RT-PCR analysis, we observed a significant increase of TLR4 expression in LPS-treated neurons and N2a cells. The LPS-induced TLR4 expression was dramatically suppressed in response to atRA treatment (Fig. 8) . These results suggest that atRA likely suppresses LPS-induced BACE1 expression through LPS receptor. Consistent with this observation, sequence analysis reveals NFB and PPAR␥/␣-RXR␣ binding sites in TLR4 promoter.
It is well known that cytoplasmic localization of inactive NFB-IB␣ complexes is controlled by both the masking of the nuclear import sequence of NFB as well as its active nuclear export. There was an additional mechanism reported (59) in which the cytoplasmic protein RasGAP SH3-binding protein 2 (G3BP2), which interacts with both IB␣ and NFB-IB complexes, anchored IB␣ or NFB-IB␣ in the cytoplasm. This novel mechanism has not been confirmed in neurons following its initial discovery in cancer cells. Interestingly, our pilot Affymetrix gene array study reveals a 3-fold up-regulation of G3BP2 in HFD C57BL/6 mouse brains, which was completely reversed by atRA to levels of the control diet mice. 5 Although we did not see altered expression of this G3BP2 gene by RA under basal conditions or with LPS addition in neurons, we cannot rule out the possibility of altered subcellular protein distribution of G3BP2 protein by atRA. The potential role of this scaffolding protein on modulation of NFB signaling in neurons under inflammatory conditions warrants further investigation.
Does atRA Mediate Differential Mechanisms of NFB Regulation under Basal Versus Inflammatory Conditions?-Our data clearly showed that atRA treatment suppressed BACE1 expression under both normal (basal) and inflammatory conditions, in vitro and in vivo. A 27% reduction in BACE1 protein expression was observed in atRA-treated C57BL/6 mice as compared with the vehicle-treated group. Moreover, we also demonstrated opposing effects of disrupting the NFB binding site on BACE1 promoter activity under basal and inflammatory conditions ( Fig. 5) , consistent with previous studies (47) . Conflicting data have been published on the inhibitory or stimulatory effects of NFB on BACE1 expression (48, 60 -62) . Our work confirms the previous study (47) showing that NFB is a repressor of BACE1 under unstressed neurons but stimulates BACE1 in activated astrocytes. Of note, although we observed a blunting effect of atRA on activated astrocytes (glial fibrillary acidic protein (GFAP)-positive cells, Fig. 2E ), especially in the hippocampal CA1 region, we found the most dominant effects of atRA on blunting neuronal BACE1 expression in both hippocampi and cortex (i.e. pyramidal neurons).
RA in CNS Inflammation-The anti-inflammatory effect of RA has been investigated for several decades, primarily in cancer, diabetes, and rheumatoid arthritis. However, it has not been studied in the CNS. There was only one study showing RA counteracting the LPS-induced inflammatory regulation of cyclooxygenase (COX)-2 mRNA and protein in astrocytes and thereby reducing the synthesis of prostaglandin E 2 (PGE 2 ) by ϳ60%. This work suggests that RA might be effective in suppressing inflammatory processes in the brain by inhibiting prostaglandin synthesis (63) . In the present study, we demonstrated that atRA down-regulates BACE1 expression under inflammatory conditions in Tg2576, HFD, and LPS-inflamed mouse brains. Together with its effects on blunting inflammatory cytokines, it raises the possibility of using atRA or other RA analogs in treatment of neuroinflammation.
Retinoid Therapy for Sporadic AD-Neuroinflammation is a local and chronic feature in Alzheimer brains that might result from and further cause the A␤ deposits (i.e. forming vicious cycles). Hence, anti-inflammatory activity and inhibition of A␤ generation are both crucial for the treatment of AD. Our current work demonstrated the dual effects of atRA on blunting BACE1 expression and neuroinflammation, suggesting a double-edged sword of atRA therapy for AD. The regulation of NFB signaling by atRA also provides a molecular link between these two pathogenic processes. It should be stressed that although the currently available AD mouse models are largely based on overexpressing one or more familial mutants of APP and/or presenilin genes, the majority of late-onset sporadic patients (Ͼ 99%) do not have a mutation that causes an increase in APP processing. Therefore, our data on atRA therapy of the HFD mice not only show reduced BACE1 expression but also have benefits in preventing weight gain, insulin resistance, and neuroinflammation and enhancing cognitive performance.
Together, this work displays promise for using retinoid therapy for sporadic AD, in particular those cases with complication of diabetes.
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